USA - NASDAQ:ANEB - US0345691036 - Common Stock
ChartMill assigns a Buy % Consensus number of 43% to ANEB. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-23 | Maxim Group | Downgrade | Buy -> Hold |
| 2025-05-15 | Maxim Group | Maintains | Buy -> Buy |
| 2024-11-19 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-10-01 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-10-03 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-09-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-21 | Maxim Group | Initiate | Buy |
| 2023-09-18 | HC Wainwright & Co. | Initiate | Buy |
| 2023-05-18 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-02-14 | Benchmark | Maintains | Speculative Buy |
| 2022-07-27 | Ladenburg Thalmann | Initiate | Buy |
| 2021-05-25 | Benchmark | Initiate | Buy |
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 209.09% is expected in the next year compared to the current price of 2.64.
The consensus rating for ANEBULO PHARMACEUTICALS INC (ANEB) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.